Meeting
2016 ASCO Annual Meeting
Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtkras metastatic colorectal cancer: A randomized phase II study (Prodige 18 –UNICANCER GI).
Authors
Sandrine Hiret
ICO René Gauducheau, Nantes, France
Sandrine Hiret , Christophe Borg , Aurelie Bertaut , Olivier Bouche , Antoine Adenis , Gael Deplanque , Eric Francois , Thierry Conroy , Francois Ghiringhelli , Gaetan Des Guetz , Jean-François Seitz , Pascal Artru , Trevor Stanbury , Marc G. Denis , Jaafar Bennouna
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT01442649
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3514)
DOI
10.1200/JCO.2016.34.15_suppl.3514
Abstract #
3514
Poster Bd #
211
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2019 Gastrointestinal Cancers Symposium
Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3.
First Author: Ryuma Tokunaga
Poster
2023 ASCO Annual Meeting
Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial.
First Author: Wensi Zhao
Poster
2023 ASCO Annual Meeting
Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO).
First Author: Patrick M Boland